JPS63255234A - Vasopressor inhibitor - Google Patents
Vasopressor inhibitorInfo
- Publication number
- JPS63255234A JPS63255234A JP62091487A JP9148787A JPS63255234A JP S63255234 A JPS63255234 A JP S63255234A JP 62091487 A JP62091487 A JP 62091487A JP 9148787 A JP9148787 A JP 9148787A JP S63255234 A JPS63255234 A JP S63255234A
- Authority
- JP
- Japan
- Prior art keywords
- beer yeast
- vasopressor
- inhibitor
- yeast
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124572 antihypotensive agent Drugs 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 239000005526 vasoconstrictor agent Substances 0.000 title abstract 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 18
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000020007 pale lager Nutrition 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】 ［産業上の利用分野］ 本発明は医薬として有用な血圧上昇抑制剤に関する。[Detailed description of the invention] [Industrial application field] TECHNICAL FIELD The present invention relates to an antihypertensive agent useful as a medicine.
［発明の背景］
カゼイン等の良質蛋白質の摂取が、血圧上昇を抑制し、
相関連して脳卒中の発生抑制に効果があることは既に知
られている（岡本耕造、近大医誌、ｖｏｌ、４．ｐ４９
，１９７８年及びＹｕｋｉｏ Ｙａｍｏｒｉ ｅｔ ａ
ｌ、。[Background of the invention] Intake of high-quality proteins such as casein suppresses blood pressure rise,
It is already known that it is effective in suppressing the occurrence of stroke (Kozo Okamoto, Kindai Medical Journal, vol. 4, p. 49).
, 1978 and Yukio Yamori et a.
l.
Ｊａｐ、）Ｉｅａｒｔ Ｊ、、Ｖｏｌ、１９．Ｐ６２４
，１９７８年参照）。Jap,) Ieart J,, Vol, 19. P624
, 1978).
一方、乾燥ビール酵母は古くから滋養強壮剤乃至は健胃
剤として活用されている。On the other hand, dried brewer's yeast has been used as a nutritional tonic or stomachic for a long time.
［：ｌＰ、明の詳述コ
乾燥ビール酵母はその成分の約５０％が蛋白質であるこ
とから、このものにも血圧上昇を抑制す′る作用がある
ことは一応予想されるが、驚くべきことに、乾燥ビール
酵母にはカゼインの薬理作用を圧倒する血圧上昇抑制作
用があり、従って、脳卒中の発生を抑制する作用がある
ことを見出した。[:lP, Akira's detailed explanation: Since approximately 50% of dried brewer's yeast is protein, it is expected that it will also have the effect of suppressing blood pressure rise, but it is surprising that In particular, it was discovered that dried brewer's yeast has a blood pressure increase suppressing effect that overwhelms the pharmacological effects of casein, and therefore has a suppressive effect on the occurrence of stroke.
［作 用］
脳卒中易発症性高血圧自然発症ラット（系統：５ＨＲ５
Ｐ、性：雄１週令：５週令から使用、体重範囲：６０〜
１００ｇ）各群１１〜１２匹ずつの４群に分け、下記の
飼料の摂取テストを行って、各群の平均体重、平均血圧
及び寿命を測定した。結果を第１〜第３図に示す。[Effect] Stroke-prone spontaneously hypertensive rats (strain: 5HR5
P, Gender: Male 1 week old: Used from 5 weeks old, Weight range: 60~
(100 g) The animals were divided into 4 groups of 11 to 12 animals each, and the following feed intake test was conducted to measure the average body weight, average blood pressure, and lifespan of each group. The results are shown in Figures 1 to 3.
Ｎｏ、２ 乾燥ビール酵母２５％含有ＳＰ
２８．９１Ｎｏ、３ 乾燥ビール酵母５０％含有
ＳＰ ３７．０９Ｎｏ、４ カゼイン２４％
含有ＳＰ ３６．６７串ケルダール法による測
定
第１図は飼料摂取テスト中のラットの体重変化を示すグ
ラフであるが、このグラフは各群の供試ラットが群によ
って異ならないほぼ一定量の飼料を摂取して順調に成育
していることを示している。この事実を踏まえて第２図
及び第３図を見ると、乾燥ビール酵母又はカゼインを配
合した市販固形飼料で飼育した供試ラット（Ｎｏ。No. 2 SP containing 25% dry beer yeast
28.91No, 3 SP containing 50% dry beer yeast 37.09No, 4 Casein 24%
Contained SP 36.67 Measurement by Kjeldahl method Figure 1 is a graph showing changes in the body weight of rats during a feed intake test. This shows that they have been ingested and are growing normally. Considering this fact and looking at Figures 2 and 3, the test rats (No.
２〜４）は、市販固形飼料だけで飼育した供試ラット（
Ｎｏ、 １ ）に比較して、血圧上昇の程度が少なく、
生存率が高いことが分かる。そして、各群の供試ラット
が摂取した飼料を対比すると、乾燥ビール酵母を２５％
配合したＮｏ、 ２の飼料は、カゼインを２４％配合し
たＮ００４の飼料より蛋白質含有量が少ないにも拘らず
、Ｎｏ、４の飼料と同程度の血圧上昇抑制作用を発揮す
る。2-4) are test rats (
Compared to No. 1), the degree of increase in blood pressure is smaller;
It can be seen that the survival rate is high. Comparing the feeds ingested by the test rats in each group, it was found that 25% of the dry brewer's yeast
Although the blended feed No. 2 has a lower protein content than the feed No. 004 containing 24% casein, it exhibits the same level of blood pressure increase suppressing effect as the feed No. 4.
また、乾燥ビール酵母を５０％配合したＮ００３の飼料
と、Ｎｏ、４の飼料を対比すると、両者は蛋白質含有量
が同程度あるが、血圧上昇抑制及び生存率の点で、前者
は後者を大幅に凌ぐ効果を発揮する。In addition, when comparing feed No. 003 containing 50% dried brewer's yeast with feed No. 4, both have similar protein content, but the former is significantly superior to the latter in terms of suppressing blood pressure rise and survival rate. Demonstrates an effect that surpasses that of
これらの試験結果から乾燥ビール酵母の血圧上昇抑制作
用は、ビール酵母に含まれる蛋白質だけに由来するもの
ではなく、ビール酵母独自の薬理作用が発現したものと
推定される。From these test results, it is presumed that the blood pressure increase suppressing effect of dried brewer's yeast is not derived only from the proteins contained in brewer's yeast, but is due to the expression of pharmacological effects unique to brewer's yeast.
本発明の血圧上昇抑制剤を人体に投与する場合は、乾燥
ビール酵母を例えば錠剤又は顆粒に成型して経口投与す
ることができ、投与量は１日当り５０ｇ以上が適当であ
る。When administering the antihypertensive agent of the present invention to the human body, dried brewer's yeast can be formed into tablets or granules and administered orally, with an appropriate dosage of 50 g or more per day.
第１〜３図はそれぞれ試験に供した脳卒中易発症性高血
圧自然発症ラットの週令と平均体重との関係、同じく週
令と平均血圧との関係、同じく週令と生存率との関係を
示すグラフである。
特許出願人 朝日麦酒株式会社
代理人弁理士 佐 １）守 雄外２名Ｏ帝ローFigures 1 to 3 show the relationship between age and average body weight, the relationship between age and average blood pressure, and the relationship between age and survival rate of the stroke-prone spontaneously hypertensive rats used in the test, respectively. It is a graph. Patent Applicant Asahi Beer Co., Ltd. Representative Patent Attorney Sa 1) Mamoru Yugai 2 people O Teiro
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62091487A JPS63255234A (en) | 1987-04-13 | 1987-04-13 | Vasopressor inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62091487A JPS63255234A (en) | 1987-04-13 | 1987-04-13 | Vasopressor inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63255234A true JPS63255234A (en) | 1988-10-21 |
Family
ID=14027769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62091487A Pending JPS63255234A (en) | 1987-04-13 | 1987-04-13 | Vasopressor inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63255234A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013084822A1 (en) * | 2011-12-08 | 2013-06-13 | アサヒグループホールディングス株式会社 | Microorganism-derived reducible mixture |
-
1987
- 1987-04-13 JP JP62091487A patent/JPS63255234A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013084822A1 (en) * | 2011-12-08 | 2013-06-13 | アサヒグループホールディングス株式会社 | Microorganism-derived reducible mixture |
| JPWO2013084822A1 (en) * | 2011-12-08 | 2015-04-27 | アサヒグループホールディングス株式会社 | Microbial derived reducing mixture |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9050323B2 (en) | Methods of treating destructive inflammation of the mucous membranes with lactoferrin | |
| JPH09512552A (en) | Methods and compositions for treating renal diseases and disorders | |
| JP2008543878A5 (en) | ||
| CA2605651C (en) | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments | |
| Ziyyat et al. | Cardiovascular effects of Arbutus unedo L. in spontaneously hypertensive rats | |
| JP2002322088A (en) | Preparation for applying onto oral cavity | |
| WO2003043639A2 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER | |
| US5580903A (en) | Liver regeneration accelerator | |
| Drayer et al. | The possible importance of aldosterone as well as renin in the long-term antihypertensive action of propranolol | |
| JPH04210924A (en) | Pharmaceutical composition for oral admini- stration of calcitonin and its dosage form | |
| JPS6345218A (en) | Antidepressive treatment using d-fenfluramine | |
| US6339104B1 (en) | Therapeutic agent for primary biliary cirrhosis | |
| JP2020506204A (en) | Composition for cough | |
| JPS63255234A (en) | Vasopressor inhibitor | |
| JPH01261334A (en) | Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof | |
| JPS6237615B2 (en) | ||
| KR100304312B1 (en) | Zinc Supplemented Prostate Extract | |
| US4416898A (en) | Therapeutic uses of methionine | |
| JP2905911B2 (en) | Agent for suppressing or increasing the number of helper T cells in AIDS | |
| JP3393304B2 (en) | Oral preparation for treatment or prevention of hyperlipidemia | |
| JPS6050165B2 (en) | Stroke prevention agent | |
| JP4221267B2 (en) | Drugs to suppress itching | |
| ST. GEORGE et al. | Correlation of serum potassium concentrations with the blood pressure in rats fed a potassium-deficient ration | |
| Nagasaka et al. | Effect of Fusaric Acid (a dopamine β‐hydroxylase inhibitor) on Phaeochromocytoma | |
| JPH07179347A (en) | Antiviral composition |